medigraphic.com

2016, Número S2

<< Anterior Siguiente >>

Rev Mex Anest 2016; 39 (S2)


Concentrado de fibrinógeno: una opción en el manejo de la hemorragia aguda

Pérez-Calatayud ÁA, Anica-Malagón ED, Zavala-Barrios B, González-Hernández G, Carrillo-Esper R

Idioma: Español
Referencias bibliográficas: 53
Paginas: 300-304
Archivo PDF: 180.70 Kb.


FRAGMENTO

La hemorragia crítica y el desarrollo de coagulopatía se asocian a un incremento de la morbilidad y mortalidad. El control de la hemorragia y manejo de la coagulopatía son piedra angular del manejo transfusional de estos pacientes; sin embargo, el uso de hemoderivados alogénicos se encuentra asociado a complicaciones. La transfusión de plaquetas y plasma fresco congelado son utilizados para el remplazo de los componentes humorales y celulares de la coagulación. Aunado a las complicaciones derivadas del estado de choque en el que se encuentra un paciente con hemorragia masiva los protocolos de transfusión masiva, a pesar de salvar la vida del enfermo no están libres de complicaciones y están asociados incluso a incremento del riesgo de muerte, aumento de días de estancia hospitalaria, aumento en el número de complicaciones asociadas a la falla multiorgánica y un aumento en los costos de atención. Por otra parte grandes cantidades de plasma han sido asociadas con complicaciones transfusionales infecciosas y no infecciosas, las cuales impactan la sobrevivencia del paciente de manera negativa.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wikkelso A, Lunde J, Johansen M, Moller AM, Afshari A, Stensballe J. Fibrinogen concéntrate in bleeding patients. Cochrane Database Syst Rev. 2013;8:CD008864.

  2. Mann KG. Thrombin formation. Chest. 2003;124:4S-10S.

  3. Mackman N. Role of tissue factor in hemostasis, thrombosis and vascular development. Arterioscler Thromb Vasc Biol. 2004;24:1015-1022.

  4. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med. 2002;196:561-564.

  5. Carr JM, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol. 1989;91:280-287.

  6. Páramo JA, Pérez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost. 1990;64:3-6.

  7. Frith D, Brohi K. The acute coagulopathy of trauma shock: clinical relevance. Surgeon. 2010;8:159-163.

  8. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003;55:39-44.

  9. Lunde J, Stensballe J, Wikkelso A, Johansen M, Afshari A. Fibrinogen concentrate for bleeding- a systematic review. Acta Anaesthesiol Scand. 2014;58:1061-1074.

  10. Spahn DR, Bouillon B, Ceny V, Coats TJ, Duranteau J, Fernández-Mondejar E, et al. Management of bleeding and coagulopathy following major trauma: an update European guideline. Crit Care. 2013;17: R76.

  11. Krozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiolo. 2013;30:270-382.

  12. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562.

  13. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667-2674.

  14. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008;248:447-458.

  15. Inaba K, Lustenberger T, Rhee P, Holcomb JB, Blackbourne LH, Shulman I, et al. The impact of platelet transfusion in massively transfused trauma patients. J Am Coll Surg. 2010;211:573–579.

  16. Wallis JP. Transfusion-related acute lung injury (TRALI)-underdiagnosed and under-reported. Br J Anaesth. 2003;90:573-576.

  17. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PG, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg. 2010;210:957-965.

  18. Watson GA, Sperry JL, Rosengart MR, Minei JP, Harbrecht BG, Moore EE, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma. 2009;67:221-227.

  19. Inaba K, Branco BC, Rhee P, Holcomb JB, Blackbourne LH, Shulman I, et al. Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients. Arch Surg. 2010;145:899-906.

  20. KreuzW, Meili E, Peter-Salonen K, Dobrkovska A, Devay J, Haertel S, et al. Pharmacokinetic properties of a pasteurized fibrinogen concentrate. Transfus Apher Sci. 2005;32:239-246.

  21. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Anna N Y Acad Sci. 2001;936:11-30.

  22. Caudill JS, Nichols WL, Plumhoff EA, Schulte SL, Winters JL, Gastineau DA, et al. Comparison of coagulation factor XIII contents and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion. 2009; 49: 765-770.

  23. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sorensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth. 2008;101:769-773.

  24. Blome M, Isgro F, Kiessling AH, Skuras J, Haubelt H, Hellstern P, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost. 2005;93:1101-1107.

  25. Bolliger D, Gonsahn M, Levy JH, Williams WH, Tanaka KA. Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery? Transfusion. 2009;49:2006-2007.

  26. Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010;113:1205-1219.

  27. Jansen JO, Thomas R, Loudon MA, Brooks A. Damage control resuscitation for patients with major trauma. BMJ. 2009;338:b1778.

  28. Sorensen B, Larsen OH, Rea CJ, Tang M, Foley JH, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. Semin Thromb Hemost. 2012;38:268-273.

  29. Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S, Fanning R, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage – an observational study. Transfus Med. 2012;22:344-349.

  30. Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995;81:360-365.

  31. Schlimp CJ, Voelckel W, Inaba K, Maegele M, Ponschab M, Schöchl H. Estimation of plasma fibrinogen levels based on hemoglobin, base excess and Injury Severity Score upon emergency room admission. Crit Care. 2013;17:R137.

  32. Schöchl H, Forster L, Woidke R, Solomon C, Voelckel W. Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate. Anaesthesia. 2010;65:199-203.

  33. Brenni M, Worn M, Brüesch M, Spahn DR, Ganter MT. Successful rotational thromboelastometry-guided treatment of traumatic haemorrhage, hyperfibrinolysis and coagulopathy. Acta Anaesthesiol Scand. 2010;54:111-117.

  34. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14:R55.

  35. Schöchl H, Nienaber U, Maegele M, et al. Transfusion in trauma: thromboelastometry guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma based therapy. Crit Care. 2011;15:R83.

  36. Wafaisade A, Lefering R, Maegele M, et al; Trauma Registry of DGU. Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge. J Trauma Acute Care Surg. 2013;74:387-393, discussion 393 -395

  37. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17:R76.

  38. Nuttall GA, Oliver WC, Santrach PJ, Bryant S, Dearani JA, Schaff HV, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology. 2001;94:773-781.

  39. Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg. 2011;142:662-667.

  40. Karlsson M, Ternström L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion. 2008;48:2152-2158.

  41. Karlsson M, Ternström L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost. 2009;102:137-144.

  42. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013;118:40-50.

  43. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth. 2009;102:785-792.

  44. Rahe-Meyer N, Solomon C, Winterhalter M, et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg. 2009;138:694-702.

  45. Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth. 2010;104:555-562.

  46. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol. 2009;114:1326-1331.

  47. Nielsen VG, Levy JH. Fibrinogen and bleeding: old molecule new ideas. Anesth Analg. 2007;105:902-903.

  48. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease of fibrinogen is an early predictor of the se- verity of postpartum hemorrhage. J Thromb Haemost. 2007;5:266-273.

  49. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica. 2007;92:846-849.

  50. Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care. 2011;15:R239.

  51. Makino S, Takeda S, Kobayashi T, Murakami M, Kubo T, Hata T, et al. National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan: investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res. 2015;41:1155-1160.

  52. Stensballe J, Ostrowski SR, Johansson PI. Viscoelastic guidance of resuscitation. Curr Opin Anaesthesiol. 2014;27:212-218.

  53. Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol. 2010;149:834-843.




2020     |     www.medigraphic.com